The Role of Perioperative Levosimendan in Patients with Reduced Ejection Fraction undergoing Cardiac surgery in Reducing Post-operative Hemodynamic Support

Mohamed Fakher; Mohamed Aboelghet; Ayman Moharam; Mahmoud Khaled; Ahmed Abdelaziz

doi:10.3889/oamjms.2022.8898

Authors

Mohamed Fakher Department of Critical Care, Faculty of Medicine, Cairo University, Giza, Egypt
Mohamed Aboelghet Department of Critical Care, Faculty of Medicine, Cairo University, Giza, Egypt
Ayman Moharam Department of Critical Care, Faculty of Medicine, Cairo University, Giza, Egypt
Mahmoud Khaled Department of Critical Care, Faculty of Medicine, Cairo University, Giza, Egypt
Ahmed Abdelaziz Department of Critical Care, Faculty of Medicine, Cairo University, Giza, Egypt

DOI:

https://doi.org/10.3889/oamjms.2022.8898

Keywords:

Post-operative, Cardiac surgery, Inotropic agentsl, Hemodynamics support, Levosimendan

Abstract

BACKGROUND: Acute perioperative left ventricular dysfunction is a major complication affecting patients subjected to cardiac surgery and is associated with increased mortality. Levosimendan as a “calcium sensitizers” with inodilator effect improves myocardial contractility by sensitizing troponin C to calcium without increasing myocardial oxygen consumption and without impairing relaxation and diastolic function.

AIM: The aim of this study was to evaluate the effect of perioperative levosimendan compared to the conventional management used in the patient with poor left ventricular function undergoing cardiac surgery to reduce the need of post-operative pharmacological and mechanical circulatory support.

METHODS: It is prospective observational studies were patients undergoing cardiac surgery divided into two groups of 25 patients each. The first group received conventional management while the other group received levosimendan additionally duration and type of post-operative pharmacological support, duration of mechanical ventilation, durations of ICU and hospital stays, and major outcomes, and data about the need of mechanical support were collected.

RESULTS: In the levosimendan, fewer patients required vasoactive agents post-surgery (Noradrenaline) compared to the conventional group, yet the use of inotropic support (adrenaline) in the 2^ndday and the need of mechanical circulatory support was equal in both groups. The mortality was equal in both groups.

CONCLUSION: Perioperative levosimendan may reduce the need of vasoactive agents postoperatively, but it does not reduce the need of inotropic nor mechanical support.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA trial. J Am Coll Cardiol. 2007;49(6):716-26. https://doi.org/10.1016/j.jacc.2006.10.048 PMid:17291938 DOI: https://doi.org/10.1016/j.jacc.2006.10.048

Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376(21):2032-42. https://doi.org/10.1056/nejmoa1616218 PMid:28316276 DOI: https://doi.org/10.1056/NEJMoa1616218

Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376(21):2021-31. https://doi.org/10.1056/nejmoa1616325 PMid:28320259 DOI: https://doi.org/10.1056/NEJMoa1616325

Rudiger A, Businger R, Streit M, Schmid ER, Maggiorini M, Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Med Wkly. 2009;139(7-8):110-6. https://doi.org/10.4414/smw.2010.13125 PMid:19234879 DOI: https://doi.org/10.4414/smw.2010.13125

Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, et al. Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care. 2010;14(2):201. https://doi.org/10.1186/cc8153 PMid:20497611 DOI: https://doi.org/10.1186/cc8153

Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-46. https://doi.org/10.1097/ccm.0b013e318232962a PMid:21963578 DOI: https://doi.org/10.1097/CCM.0b013e318232962a

Butterworth JF, Legault C, Royster RL, Hammon JW. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg. 1998;86(3):461-7. https://doi.org/10.1213/00000539-199803000-00002 PMid:9495394 DOI: https://doi.org/10.1213/00000539-199803000-00002

Romson JL, Leung JM, Bellows WH, Bronstein M, Keith F, Moores W, et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology. 1999;91(5):1318-28. https://doi.org/10.1097/00000542-199911000-00024 PMid:10551583 DOI: https://doi.org/10.1097/00000542-199911000-00024

Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg. 2002;73(1):325-30. https://doi.org/10.1016/s0003-4975(01)02719-9 PMid:11834047 DOI: https://doi.org/10.1016/S0003-4975(01)02719-9

Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006;20(3):353-7. https://doi.org/10.1053/j.jvca.2006.02.012 PMid:16750735 DOI: https://doi.org/10.1053/j.jvca.2006.02.012

Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs. 2001;61(5):613-27. https://doi.org/10.2165/00003495-200161050-00006 PMid:11368286 DOI: https://doi.org/10.2165/00003495-200161050-00006

McBride BF, White CM. Levosimendan: Implications for clinicians. J Clin Pharmacol. 2003;43(10):1071-81. DOI: https://doi.org/10.1177/0091270003257217

Frishman WH. Advances in positive inotropic therapy: Levosimendan. Crit Care Med. 2003;31(9):2408-9. https://doi.org/10.1097/01.ccm.0000084861.07091.f3 DOI: https://doi.org/10.1097/01.CCM.0000084861.07091.F3

Lehtonen LA. Levosimendan: A parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs. 2001;10(5):955-70. https://doi.org/10.1517/13543784.10.5.955 PMid:11322869 DOI: https://doi.org/10.1517/13543784.10.5.955

Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90(1):5-11. https://doi.org/10.1097/00000539-200001000-00003 PMid:10624967 DOI: https://doi.org/10.1097/00000539-200001000-00003

Greco T, Calabrò MG, Covello RD, Greco M, Pasin L, Morelli A, et al. A bayesian network meta-analysis on the effect of inodilatory agents on mortality. Br J Anaesth. 2015;114(5):746-56. https://doi.org/10.1093/bja/aeu446 PMid:25652947 DOI: https://doi.org/10.1093/bja/aeu446

Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, et al. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82-7. https://doi.org/10.1016/j.ijcard.2011.07.022 PMid:21784540 DOI: https://doi.org/10.1016/j.ijcard.2011.07.022

Khaled M, Almogy AN, Shehata M, Ragab F, Zeineldin K. Effect of levosimendan compared to conventional inotropic agents on hemodynamics and outcome in patient with poor LV function undergoing cardiac surgery. Open Access Maced J Med Sci. 2019;7(19):3205-10. https://doi.org/10.3889/oamjms.2019.675 PMid:31949517 DOI: https://doi.org/10.3889/oamjms.2019.675

Huseddinoviae I, Barišin S, Bradic N, Barišin A, Sonicki Z, Milanoviae R. Levosimendan as a new strategy during off-pump coronary artery bypass grafting: Double-blind randomized placebo-controlled trial. Croat Med J. 2005;46(6):950-6. PMid:16342349

Leppikangas H, Järvelä K, Sisto T, Maaranen P, Virtanen M, Lehto P, et al. preoperative levosimendan infusion in combined aortic valve and coronary artery bypass surgery. Surv Anesthesiol. 2011;55(6):263. https://doi.org/10.1097/sa.0b013e31823766b0 DOI: https://doi.org/10.1097/SA.0b013e31823766b0

Álvarez J, Bouzada M, Fernández ÁL, Caruezo V, Taboada M, Rodríguez J, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol. 2006;59(4):338-45. https://doi.org/10.1016/s1885-5857(06)60770-6 PMid:16709386 DOI: https://doi.org/10.1016/S1885-5857(06)60770-6

Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. Hemodynamic effects of levosimednan for low cardiac output after cardiac surgery: A case series. Hellenic J Cardiol. 2007;48(2):80-8. PMid:17489345

Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass: A four-times masked controlled study. J Cardiovasc Pharmacol. 2004;44(6):703-8. https://doi.org/10.1097/00005344-200412000-00013 PMid:15550791 DOI: https://doi.org/10.1097/00005344-200412000-00013

Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17(3):125-30. https://doi.org/10.3410/f.727935690.793535356 PMid:23620700 DOI: https://doi.org/10.3410/f.727935690.793535356

Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102(2):198-204. https://doi.org/10.1093/bja/aen367 PMid:19151048 DOI: https://doi.org/10.1093/bja/aen367

Gandham R, Syamasundar A, Ravulapalli H, Karthekeyan RB, Vakamudi M, Kodalli R, et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/replacement for severe mitral stenosis. Ann Card Anaesth. 2013;16(1):11-5. https://doi.org/10.4103/0971-9784.105363 PMid:23287080 DOI: https://doi.org/10.4103/0971-9784.105363

Tasouli A, Papadopoulos K, Antoniou T, Kriaras I, Stavridis G, Degiannis D, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of early use. Eur J Cardiothorac Surg. 2007;32(4):629-33. https://doi.org/10.1016/j.ejcts.2007.11.001 PMid:17702589 DOI: https://doi.org/10.1016/j.ejcts.2007.07.010

Lee CT, Lin YC, Yeh YC, Chen TL, Chen CY. Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery: A meta-analysis with trial sequential analysis. Intensive Care Med. 2017;43(12):1929-30. https://doi.org/10.1007/s00134-017-4927-5 PMid:28884347 DOI: https://doi.org/10.1007/s00134-017-4927-5